A randomized controlled trial to compare protection in adolescents between different meningococcal immunization schedules used in Canada           


The overall objective is to determine if the adolescent MenACWY booster in different Canadian provincial schedules provides protection at Grade 12 (age 16-17 years), as students enter the high-risk period. We will assess the initial booster response and antibody persistence following a single dose of MenACWY conjugate vaccine, comparing: (i) adolescents primed with different MenC conjugate vaccine schedules; and (ii) immunogenicity of -CRM, -DT and -TT MenACWY conjugate vaccines.

Project Lead:
Dr. Manish Sadarangani